10-Q: Perrigo Q3 Sees Profit Rebound Amid Strategic Shifts

Perrigo Company plc reported a significant improvement in net income for Q3 2025, turning a prior-year loss into a profit, despite a decline in net sales, as strategic restructuring and divestitures continue.

Summary

• Net sales for the three months ended September 27, 2025, decreased by $44.2 million (4.1%) to $1,043.3 million, primarily due to lower sales in the Nutrition category and divested businesses.
• Net sales for the nine months ended September 27, 2025, decreased by $91.6 million (2.8%) to $3,143.5 million, also impacted by prior year divestitures and soft OTC category consumption.
• Gross profit for the three months decreased by $27.3 million to $377.1 million, with gross profit margin declining by 110 basis points to 36.1%.
• Gross profit for the nine months decreased by $24.5 million to $1,132.3 million, but gross profit margin increased by 20 basis points to 36.0%.
• Operating income for the three months decreased by $7.8 million (9.7%) to $72.6 million.
• Operating income for the nine months significantly improved to $164.9 million from a loss of $1.3 million in the prior year.
• Net income for the three months was $7.5 million, a substantial improvement from a net loss of $21.0 million in the prior year.
• Net loss for the nine months improved to $7.3 million from a loss of $127.3 million in the prior year.
• Basic and diluted EPS for the three months were $0.05, up from $(0.15) in the prior year.
• Basic and diluted EPS for the nine months were $(0.05), up from $(0.93) in the prior year.
• Net cash from operating activities increased by $12.8 million to $63.1 million for the nine months.
• The company entered into a binding agreement to sell its Dermacosmetics branded business for up to €327 million, expected to close in Q1 2026.
• The Richard Bittner Business was sold on April 11, 2025, for $14.4 million, resulting in a $1.6 million pre-tax loss.
• A strategic review of the infant formula business was announced on November 5, 2025, to assess alternatives and reassess a $240 million investment.
• The IRS issued an opinion on September 25, 2025, predominantly siding with Perrigo U.S. on omeprazole and ANDA tax issues for the 2009-2012 tax years, though it is not yet a final judgment.
• The company expects a tax benefit of $28.0 million for 2025 due to the enactment of the One Big Beautiful Bill Act (OBBBA).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While net sales declined, the company achieved a significant turnaround in net income and operating income from prior-year losses, driven by strategic initiatives and cost management. Positive developments in tax litigation and resolution of some legal cases are notable. However, ongoing macroeconomic uncertainties, challenges in the infant formula business, and remaining significant legal risks temper the overall sentiment.

Positives

• Net income for the three months ended September 27, 2025, improved significantly to $7.5 million from a net loss of $21.0 million in the prior year.
• Operating income for the nine months ended September 27, 2025, showed a substantial turnaround, reaching $164.9 million compared to a loss of $1.3 million in the prior year.
• Net cash from operating activities increased by $12.8 million to $63.1 million for the nine months, indicating improved operational cash generation.
• The company expects a $28.0 million tax benefit in 2025 from the enactment of the One Big Beautiful Bill Act (OBBBA).
• A U.S. District Court opinion predominantly sided with Perrigo U.S. on key omeprazole and ANDA tax issues for the 2009-2012 tax years, potentially reducing significant tax liabilities.
• Several securities litigation opt-out cases have been settled or dismissed, including a $97.0 million class action settlement and multiple individual cases.
• The company successfully moved to dismiss all Ranitidine claims against it in the MDL based on federal preemption and scientific causation, with appeals ongoing.
• Settlements in principle for Ranitidine lawsuits in Illinois and California state courts were reached for immaterial amounts, expected to be fully funded by insurance.
• The Dermacosmetics branded business divestiture for up to €327 million is expected to close in Q1 2026, streamlining the portfolio and providing cash.
• The Supply Chain Reinvention Program is expected to generate $200 million to $300 million in annual run-rate savings by the end of fiscal year 2028, with $150 million to $200 million anticipated by the end of fiscal year 2025.
• Project Energize is expected to deliver annualized pre-tax savings of $140 million to $170 million by the end of 2026, enhancing organizational agility.

Negatives

• Net sales decreased by 4.1% for the three months and 2.8% for the nine months ended September 27, 2025, primarily due to lower sales volumes and divested businesses.
• Gross profit margin decreased by 110 basis points for the three months, driven by lower net sales volumes and less favorable store brand product mix in CSCA.
• Operating income for the three months decreased by 9.7% due to lower gross profit flow-through.
• Loss from discontinued operations increased to $5.2 million for the three months and $19.6 million for the nine months.
• Net cash used in investing activities decreased by $166.8 million for the nine months, primarily due to the absence of large divestiture proceeds from the prior year.
• Net cash used in financing activities decreased by $709.2 million for the nine months, mainly due to the absence of prior year debt issuances.
• The Nutrition category in CSCA experienced a 21.5% decrease in net sales for the three months, impacted by lost distribution of the Good Start brand and strong prior-year comparables.
• The company continues to face higher costs and lower manufacturing output in its infant formula business due to enhanced quality protocols and regulatory changes.
• The Richard Bittner Business divestiture resulted in a pre-tax loss of $1.6 million.
• The company recorded an asset impairment of $1.5 million related to its Prevacid definite-lived intangible asset due to an expected long-term decline in contribution margin.

Risks

• Macroeconomic uncertainty, including inflation, interest rates, volatile foreign currency exchange rates, tariffs, political unrest, and legislative/regulatory changes, could reduce sales or erode operating margins.
• Increased tariffs by the U.S. or foreign governments could materially increase the cost of goods for products and materials sourced from other countries, particularly China, with an estimated gross increase to global COGS of $10 million to $20 million in Q4 2025 and $40 million to $50 million on a full-year basis.
• Ongoing supply chain disruptions in specific categories (e.g., agricultural commodities due to climate impacts) and shortages due to geopolitical conflicts (e.g., Middle East Conflict) could impact operations.
• The war in Ukraine and any escalation thereof, including economic and political sanctions, could negatively impact results from operations in the region.
• Escalation of conflicts in other regions, such as the Middle East, could disrupt supply chains, particularly for Active Pharmaceutical Ingredients (API) sourced from Israel, and lead to further inflationary pressures.
• The infant formula business faces heightened competition from existing and new entrants, particularly due to continued regulatory forbearance allowing imported infant formulas, hindering market share recovery.
• The outcome of price-fixing lawsuits related to the former Rx business remains uncertain, with bellwether trials scheduled through 2026 and 2027, and a liability of $31.0 million recorded for these claims.
• The company is named in approximately 215 individual talcum powder product liability lawsuits, with trials scheduled throughout 2025 and 2026, and a substantial majority of 36+ trials set for late 2025 expected to be postponed.
• Appeals are pending in the 11th Circuit for the Ranitidine MDL dismissal, and in the Second Circuit for the Acetaminophen and Phenylephrine MDL dismissals, which could reverse favorable trial court rulings.
• The IRS audit outcome for 2009-2012 tax years, while predominantly favorable, is not yet a final, appealable judgment, and the company is considering appealing portions that sided with the government; an adverse ruling could lead to additional tax liability of $25.0 million to $128.0 million for subsequent periods.
• Future period earnings may be adversely impacted by litigation costs, settlements, penalties, and/or interest assessments related to various legal and tax matters.
• Credit ratings (Ba2 negative, BBstable, BB negative) are subject to revision and could impact future borrowing costs, access to capital markets, and vendor financing terms.
• If operational results continue to decline in certain jurisdictions where the company has deferred tax assets that rely on future taxable income, primarily the United States, an additional valuation allowance may be required, which could be a material charge to income tax expense.

Future Outlook

The company is focused on achieving sustainable and value-accretive growth through consumer-led innovation, driving category growth, strengthening its supply chain, and evolving its global operating model. Key initiatives like the Supply Chain Reinvention Program and Project Energize are expected to deliver significant cost savings and enhance organizational agility. A strategic review of the infant formula business is underway to accelerate cash flows and reassess investments, while the Oral Care business review continues. The company anticipates a tax benefit from the OBBBA in 2025 and believes its operations and borrowing resources are sufficient for future capital requirements, though it continues to monitor macroeconomic and geopolitical uncertainties.

Management Comments

• Our vision is 'To Provide The Best Self-Care For Everyone' and our purpose is to 'Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All'.
• Our strategic goal is to create sustainable and value accretive growth by delivering consumer preferred brands and innovation, driving category growth with our customers, powering our business with our world-class, quality assured supply chain, and evolving our global organization to one cohesive operating model.
• Our unique competency is to deliver health and wellness solutions across multiple price and value tiers that improve access and choice for consumers.
• Our plan to drive cash flow and total shareholder return is anchored behind its Three-S plan: Stabilizing Consumer Self-Care Americas store brand and infant formula businesses; Streamlining the global portfolio, enterprise operating model and Consumer Self-Care International business; and Strengthening what is working by prioritizing and increasing investments behind key High-Grow brands.
• Management believes that our operations and borrowing resources are sufficient to provide for our short-term and long-term capital requirements.

Industry Context

Perrigo operates in the consumer self-care market, a segment driven by consumer demand for accessible and affordable health and wellness solutions. The industry is influenced by macroeconomic factors such as inflation, interest rates, and supply chain stability. Heightened competition, particularly in the infant formula market due to regulatory forbearance allowing imported products, is a notable trend. The company's strategic focus on portfolio optimization through divestitures (Dermacosmetics, Richard Bittner) and strategic reviews (infant formula, Oral Care) aligns with a broader industry trend of companies streamlining operations to focus on core, higher-margin businesses. The ongoing legal challenges, particularly in areas like talcum powder and previously ranitidine, reflect the significant product liability risks inherent in the pharmaceutical and consumer health sectors.

Comparison to Industry Standards

• Perrigo's net sales decline of 4.1% for the three months and 2.8% for the nine months suggests underperformance relative to some growth-oriented consumer health companies, but could be influenced by its ongoing portfolio streamlining and divestitures.
• The significant improvement in net income from a loss to a profit for the three and nine-month periods indicates effective cost management and restructuring benefits, which is a positive sign in a challenging macroeconomic environment, potentially outperforming peers struggling with profitability.
• The company's gross profit margin of 36.1% (three months) and 36.0% (nine months) is within the typical range for consumer health and OTC product manufacturers, though the three-month decline suggests pricing pressures or unfavorable product mix compared to the prior year.
• The strategic review of the infant formula business, following quality issues and market share challenges, reflects a common industry response to underperforming or high-risk segments, similar to how other large consumer goods companies periodically divest non-core assets.
• The estimated annual run-rate savings of $200 million to $300 million from the Supply Chain Reinvention Program and $140 million to $170 million from Project Energize are substantial and, if achieved, could position Perrigo favorably against competitors by improving operational efficiency and cost structure.
• The predominantly favorable outcome of the IRS tax litigation, if finalized, would be a significant win, potentially avoiding large liabilities that could otherwise strain financial resources compared to companies facing similar tax disputes.

Management Changes

Legal Proceedings

• Price-Fixing Lawsuits: Consolidated in In re Generic Pharmaceuticals Pricing Antitrust Litigation MDL No. 2724. Bellwether cases (Clobetasol, Clomipramine, State AG) are proceeding, with class certification appeals accepted. Humana bellwether trial scheduled for September 15, 2026. Third phase bellwether cases (Kroger, Cigna, CVS) for 2027. State Attorney General complaint remanded to District of Connecticut, summary judgment briefing ongoing. Canadian class action dismissal pending. A $31.0 million liability is recorded for these claims.
• Securities Litigation (U.S.): Class action settlement for $97.0 million received final approval on September 5, 2024. Six opt-out cases settled in 2025, with three fully approved and three in principle. The Sculptor Master Fund case ruling, stating plaintiffs failed to opt out, was affirmed by the Third Circuit. Massachusetts state court case resolved by settlement.
• Securities Litigation (Israel): A class action complaint filed in Tel Aviv District Court is stayed pending the outcome of the U.S. Roofer's case. Plaintiff seeks preliminary damages estimate of 2.7 billion NIS (approximately $760.0 million).
• Talcum Powder: Approximately 215 individual lawsuits alleging mesothelioma and lung cancer due to asbestos in talcum powder products. Trials are scheduled throughout 2025 and 2026, with a substantial majority of 36+ trials set for late 2025 expected to be postponed. Two cases are set for trial in Alameda County, California in November and December 2025.
• Ranitidine: MDL claims against the company were dismissed with prejudice on July 8, 2021, based on federal preemption and scientific causation. Appeals are filed to the U.S. Court of Appeals for the 11th Circuit, with oral arguments held on October 10, 2025. Settlements in principle for immaterial amounts have been reached in Illinois and California state court lawsuits, expected to be fully funded by insurance. New Mexico state court granted motion to dismiss.
• Acetaminophen: Consolidated in MDL No. 3043. The company has not been named as a defendant. Court granted motions to exclude plaintiffs' general causation expert witnesses (December 18, 2023, and July 10, 2024). Appeals are before the Second Circuit, with argument scheduled for November 17, 2025.
• Phenylephrine: Consolidated in MDL No. 3089. Court dismissed the bellwether complaint on October 29, 2024, finding claims preempted by federal law and RICO claims lacking standing. An appeal to the Second Circuit has been filed, and appellate briefing is fully submitted.
• IRS Audits (Transfer Pricing and ANDA issues): A U.S. District Court opinion on September 25, 2025, predominantly sided with Perrigo U.S. on omeprazole and ANDA issues for the 2009-2012 tax years, though it is not a final judgment. The company is considering appealing portions that sided with the government. Potential additional tax liability of $25.0 million to $128.0 million for subsequent periods if the omeprazole issue is not ultimately sustained. A NOPA for 2013-2015 tax years proposed $141.6 million in transfer pricing and $21.9 million in ANDA adjustments. A NOPA for 2015-2018 tax years to reduce deductible interest expense by $348.2 million is fully reserved. The Athena Neurosciences tax dispute was favorably resolved on April 14, 2025, with an immaterial impact.

Stakeholder Impact

• Shareholders: Potential positive impact from improved profitability, strategic divestitures, and favorable tax litigation outcome. However, ongoing legal risks and uncertainties in the infant formula business could create volatility.
• Employees: Project Energize is expected to result in a net reduction of approximately 6% of total Perrigo roles, impacting employment.
• Customers: Supply Chain Reinvention Program aims to improve service levels to retail partners. Infant formula business challenges and strategic review could impact product availability and relationships with contract manufacturing customers.
• Suppliers: Middle East conflicts and tariffs could disrupt supply chains, particularly for API sourced from Israel, potentially requiring engagement with alternate suppliers.
• Creditors: Compliance with all debt covenants as of September 27, 2025, is positive. Credit rating reviews could impact future borrowing costs.

Next Steps

• Close the sale of the Dermacosmetics branded business in the first quarter of 2026.
• Continue the strategic review of the infant formula business, assessing alternatives and reassessing the $240 million investment.
• Continue the strategic review of the Oral Care business.
• Submit computations implementing the IRS refund case opinion or briefs explaining disagreements by December 19, 2025.
• Monitor and defend against ongoing price-fixing lawsuits, with bellwether trials scheduled through 2026 and 2027.
• Vigorously defend against approximately 215 individual talcum powder lawsuits, with trials scheduled throughout 2025 and 2026.
• Await outcomes of appeals in the 11th Circuit for Ranitidine MDL and in the Second Circuit for Acetaminophen and Phenylephrine MDLs.
• Continue to implement the Supply Chain Reinvention Program to achieve $200 million to $300 million in annual run-rate savings by the end of fiscal year 2028.
• Continue to implement Project Energize to deliver annualized pre-tax savings of $140 million to $170 million by the end of 2026.
• Monitor regulatory developments for the OECD's Pillar Two initiative and other tax law changes.

Key Dates

Recommendation

Perrigo is in a significant transitional phase, marked by a notable improvement in net income and operating income from prior-year losses, driven by ongoing restructuring and portfolio optimization efforts. The predominantly favorable outcome of the IRS tax litigation is a material positive, though not yet final. Strategic divestitures and efficiency programs are expected to yield future benefits. However, the company faces declining net sales, persistent macroeconomic headwinds, and substantial ongoing legal and regulatory uncertainties, particularly with the talcum powder lawsuits and appeals in other product liability cases. The strategic review of the infant formula business adds another layer of uncertainty regarding future portfolio composition and financial impact. A 'hold' recommendation is appropriate for a seasoned investor, as the company navigates these complex transitions. While there are clear signs of operational improvement and strategic execution, the remaining risks and the non-final nature of some positive developments warrant a cautious stance, awaiting clearer outcomes from these critical initiatives and legal matters before making a more definitive investment decision.

Keywords

Self-Care, OTC, Consumer Health, Pharmaceuticals, SEC Filing, 10-Q, Financial Results, Restructuring, Divestitures, Infant Formula, Supply Chain, Project Energize, Dermacosmetics, Legal Proceedings, Tax Litigation, Perrigo